Nintendo Revise Sales for Wii U

Nintendo Revise Sales for Wii U

Latest bad news for Nintendo comes with the revised sales, where it faces the first annual loss in more than three decades. This Kyoto-based videogame maker reduced its full-year sales point of view for a second quarter.

Nintendo ha reduced the sales forecast for its novel Wii-U console, but still hopes to make an annual profit. This view can be attributed to the weak yen. After the disappointing sales, it has forecasted that it will sell only four million Wii-Us in the year up to March, down 27% from its preceding forecast.

The results that have arrived after end of trading on the Tokyo Stock Exchange do not speak well for the financial condition of the company. This shock is also mixed with an overall operating loss of 20bn yen for the year. Earlier, it had anticipated a 20bn-yen operating profit. Financial experts are hoping to have atleast 12bn-yen operating profit on average.

The firm has increased its annual net profit forecast to 14bn yen. All thanks goes to its failing home currency. Last year, it had incurred a loss of 43bn yen. Weaken currency has provided two-pronged benefit for the company. Firstly, it has lead to growth in the value of its foreign currency resources in short-term and secondly, it overturned its stable loss of price competitiveness against foreign competitors in the longer-term.

General: 
Technology: 
Companies: 

Popular Stories

Flu vaccine is 48% effective this season: CDC

Flu vaccine has reduced the risk of infections in... Read More

Erosion of beaches will get worse: researchers warn

Portraying a gloomy picture of the future, the 2015... Read More

Rare rat-linked disease leaves 1 dead, 2 sickened in Bronx

A rare bacterial disease carried by rats has killed... Read More

Try drug-free remedies before resorting to medication for low back pain: ACP

People suffering low back pain should try drug-free... Read More

Pregnant inmate forced to deliver baby on jail cell floor

A Detroit-area sheriff has defended his staff over... Read More

Marathon Pharma to sell decades-old drug to treat DMD for $89,000

Marathon Pharmaceuticals will reportedly market... Read More